Please login to the form below

Not currently logged in
Email:
Password:

Quizartinib

This page shows the latest Quizartinib news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

Others are however moving through the late-stage pipeline, including Daiichi Sankyo’s quizartinib and Arog Pharma’s crenolanib.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    500. Ambit Biosciences / Daiichi Sankyo. Company acquisition. Kinase inhibitor pipeline, lead compound quizartinib for AML in phase III.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Similarly Daiichi Sankyo has supplemented its oncology pipeline by acquiring Ambit Biosciences for $400m. Ambit develops kinase inhibitors and has quizartinib in phase 3 for acute myeloid leukaemia.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics